Session » Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1549

A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis: 6 – Months Clinical Outcomes from the Czech Biologic Registry Attra

9:00AM-11:00AM: Abstract Number: 1551

Avoidance of Physical Activity Leads to Reduced Inflammatory Enthesitis on Ultrasound

9:00AM-11:00AM: Abstract Number: 1562

Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes

9:00AM-11:00AM: Abstract Number: 1518

Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data

9:00AM-11:00AM: Abstract Number: 1519

Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study

9:00AM-11:00AM: Abstract Number: 1558

Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1525

Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database

9:00AM-11:00AM: Abstract Number: 1513

Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe

9:00AM-11:00AM: Abstract Number: 1538

Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1546

Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1534

Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry

9:00AM-11:00AM: Abstract Number: 1540

Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine

9:00AM-11:00AM: Abstract Number: 1507

Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1537

Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 1554

Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1553

Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1527

Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?

9:00AM-11:00AM: Abstract Number: 1547

Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)

9:00AM-11:00AM: Abstract Number: 1517

Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data

9:00AM-11:00AM: Abstract Number: 1516

Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 1531

Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 1556

Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.

9:00AM-11:00AM: Abstract Number: 1533

Efficacy of Switching Biological Dmards in Patients with Axial Spondyloarthritis: Results from a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1545

Evaluation of the Adherence to Recommendations for Tnfα Blockers Use and Its Impact over 5 Years of Follow-up in Early Axial Spondyloarthritis. Data from the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 1541

First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties

9:00AM-11:00AM: Abstract Number: 1505

Gender Bias in the Inheritance of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1520

Golimumab Retention Rate in Patients with Spondyloarthitis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1539

High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1521

Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on 52-Week Clinical Response to Adalimumab in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1515

Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204

9:00AM-11:00AM: Abstract Number: 1530

Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial

9:00AM-11:00AM: Abstract Number: 1542

Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study

9:00AM-11:00AM: Abstract Number: 1512

Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 1504

More Than 10 Percent Patients with Recent Onset Chronic Mechanical Back Pain Fulfill the Modified NY Criteria for Sacroiliitis

9:00AM-11:00AM: Abstract Number: 1561

Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1550

One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry

9:00AM-11:00AM: Abstract Number: 1548

Opioid Use in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1536

Patient Preferences in Medication for Treatment of Spondyloarthritis: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 1522

Patients with Ankylosing Spondylitis Had Better Adalimumab Survival Than Patients with Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1552

Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1514

Phenotype Differences in HLA-B27 Positive Versus Negative Patients with Ankylosing Spondylitis in a Population That Show Relatively Weaker Association with HLA-B27

9:00AM-11:00AM: Abstract Number: 1560

Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab

9:00AM-11:00AM: Abstract Number: 1511

Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1543

Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1524

Real-World Use of Secukinumab Among Biologic-NaïVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States

9:00AM-11:00AM: Abstract Number: 1559

Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1532

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year

9:00AM-11:00AM: Abstract Number: 1529

Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1523

Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1528

Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue

9:00AM-11:00AM: Abstract Number: 1526

Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 1509

Similarities and Differences between Non-Radiographic and Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1510

Similarities and Differences between Osteitis Condensans Ilii and Axial Spondyloarthritis Patients Presenting with Chronic Back Pain in a Rheumatology Setting

9:00AM-11:00AM: Abstract Number: 1506

Similarities and Differences between Patients Fulfilling Non-Radiographic Axial Spondyloarthritis and Undifferentiated Spondyloarthritis Criteria: Results from the Esperanza Cohort

9:00AM-11:00AM: Abstract Number: 1535

Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment

9:00AM-11:00AM: Abstract Number: 1544

The Effect of Extraarticular Manifestations on Tumor Necrotic Factor α Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Nationwide Data from the Korean College of Rheumatology Biologics (KOBIO) Registry

9:00AM-11:00AM: Abstract Number: 1503

The Prevalence of Axial Spondyloarthritis in Israel

9:00AM-11:00AM: Abstract Number: 1555

Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso

9:00AM-11:00AM: Abstract Number: 1557

Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting

9:00AM-11:00AM: Abstract Number: 1508

Validation of Self-Reported Inflammatory Back Pain Score Compared to Rheumatology Consultation in University Students

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].